Katie Binley

Katie Binley is a Chief Scientific Officer at ikarovec, a pre-clinical phase gene therapy company focused on treating common eye diseases. Prior to this role, Katie held positions at PepGen and Oxford Biomedica, where Katie was involved in leading research, managing non-clinical studies, and developing gene therapy programmes. With a background in yeast molecular genetics, Katie has made significant contributions to the field of gene therapy, with a focus on ocular and neurological diseases. Katie has a strong publication record and has presented their research at international conferences.